MONTREAL, QUEBEC--(MARKET WIRE)--Sep 19, 2007 -- MethylGene Inc. (Toronto:MYG.TO - News), today announced preclinical results for its histone deacetylase (HDAC) clinical candidate MGCD290 at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in Chicago.
